



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/525,006	03/28/2005	Shirou Sawa	2005_0232A	1756
513 7590 06/03/2009 WENDEROTH, LIND & PONACK, L.L.P. 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503			EXAMINER JAGOE, DONNA A	
			ART UNIT 1614	PAPER NUMBER
			MAIL DATE 06/03/2009	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

DETAILED ACTION

Claims 19-29, 31-34, 36-51, 53-56 and 58-63 are pending in this application.

Claims 39, 40, 61 and 62 are withdrawn from further consideration.

Claims 19-29, 31-34, 36-38, 41-51, 53-56, 58-60 and 63 are rejected.

Applicants' arguments filed January 15, 2009 have been fully considered but they are not deemed to be persuasive. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application.

Change of Examiner

The examiner assigned to the instant application has changed. The new examiner is Donna Jagoe. Contact information is provided at the end of this Office Action.

Priority

As recited in the Office Action dated September 27, 2007, Applicant is reminded that a certified translation has not been proved for the claim to foreign priority of JP2003-012427, filed 1/21/2003. Since no translation has been provided, prior art

dates have been determined with reference to the priority date for the PCT application date, PCT/JP04/00350, filed 1/16/2004.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 19-29, 31-34, 36-38, 41-51, 53-56, 58-60 and 63, are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 19 and 41 recite an aqueous liquid preparation comprising at least 2-amino-3-(4-bromobenzoyl)phenylacetic acid (bromfenac) and an alkyl aryl polyether alcohol type polymer or polyethylene glycol fatty acid ester "wherein said liquid preparation is in the form of an eye drop". It is unclear what is meant by "in the form of an eye drop. Is this aqueous liquid preparation in a container shaped like an eye drop? It is suggested that the claim be amended to recite "wherein said liquid preparation is formulated for ophthalmic administration".

Claim Rejections - 35 USC § 103

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claims 19-29, 31-34, 36-38, 41-51, 53-56, 58-60 and 63 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hellberg et al. (US 5,998,465; 1999) and

Nolan, et al. ("The topical anti-inflammatory and analgesic properties of bromfenac in rodents; Agents and Actions; 1988 Aug; 25(1-2):77-85; cited with previous Interview Summary).

Hellberg teaches pharmaceutical compositions of anti-inflammatory compounds (abstract); the compounds include a non-steroidal anti-inflammatory moiety (NSAIA) and an antioxidant moiety linked through an ester bond formed by the carboxylic acid moiety of the NSAIA (col. 2, lines 20-24); NSAIA moieties include bromfenac (col. 3, line 57; claim 5); examples 2 and 3 (col. 11) teach topical ophthalmic formulations useful for treating inflammation, both of these formulations include tyloxapol at 0.01-0.05 w/v %, HPMC (thickener), benzalkonium chloride (preservative), edetate disodium (chelating agent) (col. 11, Examples 2-3); the pH is adjusted to 7.4 (about 7.5; col. 11, line 64); topical formulations administered by drops (eye drops; col. 10, lines 15-18). Hellberg does not teach bromfenac (only the ester of bromfenac). Nolan teaches bromfenac (the sodium salt, sesquihydrate form) was effective as a topical analgesic at concentrations of 0.1-0.32 % in mice and more potent than the other drugs tested (abstract). It would have been obvious for one of ordinary skill in the art at the time of the invention to substitute bromfenac, taught by Nolan for the compounds of Hellberg in the example formulation giving formulations of the instant claims and to select concentrations of bromfenac sodium, sesquihydrate of 0.1, about 0.2 and about 0.32 %, in the invention of Gamache, since these values have demonstrated efficacy for topical use. It would also have been obvious to adjust the concentration of tyloxapol, to optimize the formulations for the effect would on the solubility and stability of the aqueous

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.